ASGR1 and viral infectious disease: Then, we observed that similar to cells treated with siRNA targeting ASGR1, cells treated with monoclonal anti-ASGR1 also showed a decrease in the level of SARS-CoV-2 infection (Fig. 3h, i), noting that monoclonal antibodies are not as effective in inhibiting viral infection as siRNA.